Kornimate/medical-research-clean huggingface dataset:
investigation of anthropometric properties of babies with craniosynostosis

Conditions: Craniosynostoses

Summary: craniosynostosis is a malformation affecting the head and face, in which one or more sutures in the skull are fused prematurely. premature union of one or more sutures causes changes in the shape of the skull base and dome, resulting in asymmetrical or restricted head and facial enlargement. it has been reported that in craniosynostosis, the bone enlargement is perpendicular to the fused sutures with the counterbalancing expansion. craniosynostosis usually involves the union of a single cranial suture, but in some cases it has been observed that it may involve more than one suture in the baby's skull. an asymmetrical appearance is observed on the faces of babies, especially an unusual appearance in the form of eyes and skulls. it may present with neurological defects such as hydrocephalus, mental retardation, vision and hearing loss, as well as cosmetic deformities in the skull and facial bones. the general prevalence of craniosynostosis is around 1/2500 births. generally, in single suture synostoses, there is no clear neurological finding except deformity. in multisuture synostoses there are a wide spectrum of findings such as increased intracranial pressure, hydrocephalus, syringomyelia, chiari malformation, venous anomalies, ophthalmologic problems, growth retardation and epilepsy. early diagnosis and treatment provides enough room for the baby's brain to grow and develop. it is thought that by measuring the anthropometric properties of these babies, the course of their development will be examined.

babies diagnosed with craniosynostosis at birth will be included in this study. the patients will be diagnosed using a combination of physical examination, skull radiographs and 3 dimensional computerized tomography scans.a voluntary consent form will be signed by the parents of all subjects indicating that they are willing to participate in the study. anthropometric measurements of all subjects will be measured with the star scanner device.

Eligibility criteria:
inclusion criteria: * being under 2 years old * being diagnosed with non-syndromic craniosynostosis * agreeing to participate in the study exclusion criteria: * having a craniomaxillofacial fracture * having a history of surgery * having a congenital anomaly that affects growth or development
effect of untact upper extremity rehabilitation using smart glove for late subacute and chronic patients with brain disorder

Conditions: Untact Upper Extremity Rehabilitation; Brain Disorder; Home Based Rehabilitation

Summary: the aim is to clinically validate the clinical efficacy, usability, and safety of home-based upper limb rehabilitation training using the neofect smart glove by comparing the effects between a group using the home-based neofect smart glove and a group performing conventional home-based occupational therapy in patients with upper limb dysfunction in the late subacute and chronic stages of neurological diseases.


Eligibility criteria:
inclusion criteria: * patients with brain disorder aged 19 to 85 years old * patients with hemiparesis lasting for more than 3 months due to neurological diseases (stroke, traumatic brain injury, brain tumor) and impaired upper limb function * patients with spasticity of the wrist and finger flexors and extensors on the affected side, with a modified ashworth scale (mas) score of 1+ or lower * participants with sufficient cognitive function to understand the instructions from the researcher and the smart glove, and to perform the tasks (k-mmse ≥21) exclusion criteria: * pre-existing significant neurogenic disorders * major psychiatric disorders such as schizophrenia, bipolar disorder, or dementia * history of diseases that caused pain or muscle atrophy in the affected upper limb before the onset of the neurological disease, which interfered with rehabilitation * severe spasticity of the affected upper limb (modified ashworth scale score ≥3) * skin disorders or open wounds on the affected upper limb * amputation, fractures, or soft tissue-related diseases or injuries on the affected upper limb * severe pain that interferes with rehabilitation of the affected upper limb (numeric rating scale \> 6) * inability to maintain a seated posture for more than 10 minutes * significant visual impairment to the extent that the screen cannot be recognized when using the smart glove
impact of prisma on donor site pain

Conditions: Skin Graft Disorder; Donor Site Complication

Summary: the purpose of this study is to assess the feasibility of evaluating the use of a composite collagen, silver-oxidized regenerated cellulose matrix compared to the standard of care dressing on donor site pain for patients undergoing split-thickness skin grafting in preparation for a larger study.


Eligibility criteria:
inclusion criteria: * patient scheduled to undergo stsg for any reason * patient, or designated healthcare proxy, has read and signed the irb-approved informed consent form. exclusion criteria: * active infection or history of radiation to the donor site * patient has a known sensitivity to promogran prisma™ or silver * elevated inr \>3.0 * insensate at the donor site * chronic narcotic use (\>6 months of daily use)

Keywords: donor site pain after skin graft harvesting
efficacy of polymyxin b hemoperfusion on severe sepsis secondary to pneumonia or urinary tract infection

Conditions: Sepsis

Summary: toraymyxin is an extracorporeal hemoperfusion cartridge containing polymyxin b-immobilized fiber column designed to reduce blood endotoxin levels in sepsis. meta-analysis of randomized trials showed that polymyxin b hemoperfusion significantly reduced the mortality of severe sepsis; however, the evidence was mainly contributed by the studies of abdominal sepsis. the data about using polymyxin b hemoperfusion to treat non-abdominal sepsis remain very limited. investigators designed a clinical trial to evaluate the efficacy of polymyxin b hemoperfusion on treating non-abdominal severe sepsis. the study hypothesis is that removal of endotoxin by polymyxin b hemoperfusion in patients with pneumonia or urinary tract infection (uti)-related severe sepsis will attenuate sepsis associated microcirculation failure and result in early reversal of shock and less extent of end-organ damage.


Eligibility criteria:
inclusion criteria: 1. patients with septic shock defined by the third international consensus definitions for sepsis and septic shock 2. newly diagnosed pneumonia or urinary tract infection (uti) defined as the following: 2-1. pneumonia is defined by a new infiltrate on chest radiograph and the presence of one or several of the following signs or symptoms: cough, sputum production, dyspnea, core body temperature ≥ 38.0°c, auscultatory findings of abnormal breath sounds and rales and leukocyte count \> 10000 or \< 4000/l. 2-2. uti is defined by at least one clinical symptom (core body temperature ≥38.0°c, urinary urgency, polyuria, dysuria, suprapubic pain, flank pain, costovertebral angle tenderness, nausea and vomiting) and one urinary criterion (pyuria \>20 leukocytes/μl). 3. hyperlactatemia (\>2 mmol/l) 4. endotoxin activity assay (eaa) ≥ 0.5 units. exclusion criteria: 1. shock persisted \>12 hours before screening 2. mechanical ventilation \>21 days 3. uncontrolled hemorrhage 4. thrombocytopenia (platelet count \< 30,000 cells/mm3) 5. leukopenia (leukocyte count \< 1500 cells/mm3) 6. suspected allergy to polymyxin 7. females with pregnancy 8. terminal cancer or organ failure with life expectancy less than 30 days

Keywords: polymyxin b pneumonia sepsis urinary tract infection
my coach connect: an automated telephone-based reporting system for patients with mental illness

Conditions: Chronic Mental Illness; Major Depression; Schizophrenia; Bipolar Disorder

Summary: this is a pilot study for a novel, automated telephone system called "my coach connect". the purpose of the study is to evaluate the feasibility and effectiveness of this telephone tool while engaging clients and providers in discussion groups and surveys to better understand how this tool impacts the care provided and their overall experience in healthcare.

clients will use this tool (my coach connect) to leave voice messages and survey answers which their providers will have access to by logging in to a secure website. providers will also be able to indicate using the website whether they found a particular narrative helpful or not. providers will have access to audio recordings of the voice responses, transcribed text of the responses, as well as "word clouds" generated from the text. word clouds are a method of displaying the content of text such that words that are used more frequently are displayed in a larger size than words used less frequently. clients will call in to the system approximately twice a week for a period of four months.

Eligibility criteria:
inclusion criteria: * enrolled in the roads program * english speaking * have a working telephone exclusion criteria: * must speak english

Keywords: mental illness depression schizophrenia bipolar disorder ivr automated telephone
transcriptomic and next generation sequencing approaches to infection with treponema pallidum

Conditions: Syphilis

Summary: syphilis is an important sexually transmitted infection. there has been an epidemic of syphilis amongst men who have sex with men in the united kingdom in the last decade. early infection with syphilis causes a genital ulcer followed, in the absence of treatment, by a generalised illness often accompanied by rash. studies on the pathogenesis of syphilis have been limited because it is not possible to grow syphilis outside of the body. new approaches using molecular tests allow the immune response of the patient to infection to be measured directly from a swab of a genital ulcer or rash and/or a blood sample and also allow the whole genetic sequence of the bacteria to be obtained from a swab. in this study the investigators will collect swabs from ulcers or rashes and a blood sample from patients with syphilis and measure both the response of the patient immune system and the genetic sequence of the bacteria. patients will be enrolled at sexual health clinics in the united kingdom. patients will receive standard medical care including standard treatment for syphilis in line with national guidelines. standard management already includes collection of a swab and a blood sample. for this study an additional swab sample and an additional 5ml of blood will be collected for use in this research project. by better understanding host immune system responds to infection with syphilis the studies aims to gain better insights in to the pathogenesis of this important sexually transmitted disease.


Eligibility criteria:
inclusion criteria: * early infectious syphilis with exudative skin/genital lesions from which a lesion swab can be obtained exclusion criteria: * age \<18 years * unable to provide consent * patients with other stages of syphilis apart from primary or secondary or patients without a lesion from which swabs can be obtained
bi-ventricular pacing in patients with atrial fibrillation and heart failure (biff-study)

Conditions: Heart Failure

Summary: cardiac resynchronization therapy (crt) is used to treat dilated heart failure with discoordinate contraction. dyssynchrony typically stems from electrical delay leading to mechanical delay between the septal and lateral walls. right ventricular apical pacing might be associated with long-term adverse effects on left ventricular function, and alternative pacing sites such as high septal or rvot has been suggested. previous studies have however been conflicting. the aim of this study is to determine if bi-ventricular pacing from rvot + lv is better than rvapex+lv. to avoid influence from possible atrial delay only patients with chronic atrial fibrillation are included. all patients will receive a bi-ventricular pacemaker with 3 leads placed in rvapex, rvot and via coronary sinus to pace the left ventricle. after a run in period (to determine if av-junction ablation is necessary) the patients are randomised to one of the following pacing configurations: rvot+lv or rvapex+lv with cross-over after 3 month.


Eligibility criteria:
inclusion criteria: * heart failure nyha iii-iv * lvef\<35% * qrs duration\>150 ms * chronic atrial fibrillation. exclusion criteria: * heart failure not related to systolic function * unstable angina pectoris, ami, pci or cabg within 2 month * inclusion in other studies

Keywords: heart failure dyssynchrony cardiac resynchronization therapy atrial fibrillation rvot rvapex
pharmacokinetics of chf 5993 pmdi with and without spacer in copd patients

Conditions: COPD

Summary: the study is performed to investigate the effect of the spacing device on the pharmacokinetics of chf 5993 pmdi active ingredients administered with and without aerochamber plus flow-vu antistatic vhc spacer as a single administration in copd patients. moreover, the general safety and tolerability of the treatments will be evaluated.


Eligibility criteria:
inclusion criteria: * copd patients * smokers or ex-smokers * post-bronchodilator fev1 between 30 and 60% of predicted value exclusion criteria: * positive serology to hiv and hepatitis * known respiratory disorder other than copd * recent copd exacerbations or hospitalization for copd * treatment with non-permitted concomitant medication * clinically relevant concomitant disease * clinically relevant abnormal laboratory or ecg parameters
neurobehavioral plasticity to regular sugar-sweetened beverage intake: an fmri experiment

Conditions: Obesity; Weight Gain

Summary: the proposed project will examine the strength, specificity and persistence of neurobehavioral adaptions that occur in the initial period of repeated consumption of a branded sugar sweetened beverage (ssb).

the proposed project addresses critical gaps in the understanding of the strength, specificity and persistence of neurobehavioral adaptions that occur in the initial period of repeated consumption of a branded sugar sweetened beverage (ssb). half of americans consume ssbs on any given day. regular ssb intake is considered a contributing factor to excess energy intake, weight gain, and obesity, which impacts 70% of americans. a contributing factor to repeated ssb consumption is sugar intake causes the release of dopamine (da) and opioids in the striatum, providing positive reinforcement. as such, multiple brain-based models of food reward-driven obesity have been proposed, largely focusing on the striatum and executive functioning. these brain-based models of obesity have elucidated risk factors for overconsumption of high-sugar foods; however, data supporting these competing models rely heavily on observational studies in small samples. importantly, previous reports from the investigators lab and others directly implicate eating behavior patterns as a vital contributor to aberrant neurobehavioral responses to food stimuli. however, without experimental evidence, there are fundamental gaps in the investigators knowledge about the neurobehavioral adaptations that occur as an individual begins to regularly consume a ssb prior to weight change. as observational data suggest, it is also crucial to examine individual difference factors that may exacerbate or protect against adaptations associated with regular ssb intake, as well as whether these adaptions are specific.

Eligibility criteria:
inclusion criteria: * potential participants will be eligible for the study if they have bmi scores between the 18 and 34 at baseline. exclusion criteria: * individuals with probable current axis i psychopathology or any fmri contra-indicators (e.g., metal implants, braces) will be excluded. those with a probable axis i diagnosis will be provided with treatment referral information and encouraged to seek treatment, * current regular use (3 or more times a week) of psychoactive drugs (e.g., cocaine, marijuana, nicotine), * regular smoking, * serious medical problems (e.g., cancer, diabetes), * dietary practices that do not allow intake of intervention beverages.

Keywords: nutrition obesity weight gain sugar sugar sweetened beverage dopamine neurobehavioral adaptation
breast ultrasound image reviewed with assistance of deep learning algorithms

Conditions: Breast Cancer; Breast Lesions; Breast Mass

Summary: this study evaluates a second review of ultrasound images of breast lesions using an interactive "deep learning" (or artificial intelligence) program developed by samsung medical imaging, to see if this artificial intelligence will help the radiologist make more accurate diagnoses.

using ultrasound images prospectively acquired, the purpose of this study entails a second review of ultrasound images with suspicious breast lesions using an interactive "deep learning" (or artificial intelligence) program developed by samsungmedison co.,ltd. the images will be reviewed by the radiologists twice: first without, and then with assistance of artificial intelligence program by samsungmedison co., ltd. birads system will be used in this study. the objectives of the study are twofold: to quantify the statistical equivalence of radiologists' opinion and ai's output (cade), and to check birads score-based diagnostic accuracy (cadx) that is gained by the radiologists' use of this interactive tool

Eligibility criteria:
1. inclusion criteria: * adult females or males recommended for ultrasound-guided breast lesion biopsy or ultrasound follow-up with at least one suspicious lesion * age \> 18 years * able to provide informed consent 2. exclusion criteria: * unable to read and understand english * unable or unwilling to provide informed consent * a patient with current or previous diagnosis of breast cancer in the same quadrant * unable or unwilling to undergo study procedures 3. subject characteristics 1. number of subjects: 300 subjects from 300 separate breast lesions can be acquired. if a subject has more than 1 suspicious lesion, each may be chosen by the radiologist attending as suitable for "second review". 2. gender and age of subjects: adult females or males aged 18 years or older who meet all of the inclusion criteria and none of the exclusion criteria will be considered for enrollment. minors are excluded as breast cancer is very rare in this age group. 3. racial and ethnic origin: there are no enrollment exclusions based on economic status, race, or ethnicity. based on local and united states census data, the expected ethnic distribution will be approximately 26 hispanic (approx. 16%) and 134 non-hispanic people. furthermore, the expected racial distribution is expected to be approximately 126 white (approx. 79% of the whole study), 21 black or african america (13%), 8 asian (5%), and 5 of other categories (3%). 4. vulnerable subjects: it is unlikely that any ur students or employees will be enrolled unless their primary physician refers them to ur medicine breast imaging at red creek for breast ultrasound and a suspicious lesion is found. we do not expect any of these referrals to be from staffs who work directly with the pis.

Keywords: breast cancer breast imaging
atomoxetine in the treatment of binge eating disorder

Conditions: Binge-eating Disorder

Summary: the specific aim of this study is to assess the efficacy and safety of atomoxetine compared with placebo in outpatients with binge eating disorder.


Eligibility criteria:
inclusion criteria: * subjects will meet the dsm-iv criteria for a diagnosis of binge-eating disorder for at least the last 6 months * in addition, subjects will report at least 3 binge eating episodes per week for the last 6 months prior to randomization exclusion criteria: * have concurrent symptoms of bulimia nervosa or anorexia nervosa * women who are pregnant, lactating, or of child bearing potential who are not using adequate contraceptive measures * patients who are displaying clinically significant suicidality or homicidality
rollover study for continuing nbi-98854 administration in pediatric subjects with tourette syndrome

Conditions: Tourette Syndrome

Summary: this is an open-label, rollover study to collect long-term safety, tolerability, and investigator- and participant-reported pharmacodynamic (pd) data after chronic administration of nbi-98854 in pediatric participants with tourette syndrome (ts), as well as to provide open-label access to nbi-98854 for the treatment of ts for pediatric participants who have taken part in a phase 2 nbi-98854 study.


Eligibility criteria:
inclusion criteria: 1. have a clinical diagnosis of tourette syndrome (ts) 2. have participated in the nbi-98854-ts2004 or nbi 98854-ts2005 phase 2 studies 3. if using maintenance medication(s) for ts and/or ts spectrum diagnoses (e.g. obsessive-compulsive disorder \[ocd\], attention-deficit hyperactivity disorder \[adhd\]), be on stable doses 4. be in good general health 5. subjects of childbearing potential who do not practice total abstinence must agree to use hormonal or two forms of nonhormonal contraception (dual contraception) consistently during the screening, treatment and follow-up periods of the study exclusion criteria: 1. have an active, clinically significant unstable medical condition within 1 month before screening 2. have a known history of long qt syndrome or cardiac arrhythmia 3. have a known history of neuroleptic malignant syndrome 4. have a cancer diagnosis within 3 years prior to screening (some exceptions allowed) 5. have an allergy, hypersensitivity, or intolerance to vmat2 inhibitors 6. have a blood loss ≥250 ml or donated blood within 56 days, or donated plasma within 7 days, before the start of the study 7. have a known history of substance dependence, substance (drug) or alcohol abuse within 3 months before the start of the study 8. have a significant risk of suicidal or violent behavior 9. have received an investigational drug within 30 days before the start of the study or plan to use an investigational drug (other than nbi-98854) during the study 10. are currently participating in another nbi-98854 clinical study 11. are pregnant (for females)